Table 4.
Subgroup analysis of the relationship between statin consumption and risk of developing age-related macular degeneration.
| Characteristics | Study no. | OR (95% CI) | p value | |
|---|---|---|---|---|
| Study type | Cross-sectional | 2 | 0.95 (0.59–1.53) | 0.831 |
| Cohort | 13 | 0.95 (0.82–1.09) | 0.458 | |
| Case-control | 8 | 0.92 (0.75–1.13) | 0.440 | |
|
| ||||
| Study location | North America and Canada | 13 | 0.94 (0.80–1.10) | 0.468 |
| Europe | 4 | 0.81 (0.54–1.21) | 0.308 | |
| Asia | 4 | 1.05 (0.94–1.18) | 0.362 | |
| Australia | 1 | 0.52 (0.26–1.04) | 0.125 | |
|
| ||||
| Study period | 2000–2010 | 13 | 0.91 (0.76–1.08) | 0.291 |
| 2011–2021 | 9 | 0.95 (0.81–1.11) | 0.520 | |
|
| ||||
| Follow-up period | Less than five years | 16 | 0.90 (0.78–1.04) | 0.165 |
| More than five years | 6 | 0.99 (0.81–1.22) | 0.965 | |
|
| ||||
| Sample size | >10000 | 10 | 1.02 (0.90–1.12) | 0.983 |
| ≤10000 | 12 | 0.79 (0.59–1.06) | 0.114 | |